Vertex to Tackle Liver Disease with Verve, Putting Up $60M to Partner on Gene Editing Program

Vertex Pharmaceuticals is getting deeper into in vivo gene editing. Months after partnering with Mammoth Biosciences, the storied biotech is back with another deal, ponying up $60 million to work with Verve Therapeutics on a single undisclosed liver disease.